Access options
Nature 552, S67-S69 (2017)
doi: https://doi.org/10.1038/d41586-017-08702-7
This article is part of Nature Outlook: Cancer immunotherapy, an editorially independent supplement produced with the financial support of third parties. About this content.
Updates & Corrections
-
Correction 22 December 2017: An earlier version of this article overstated the number of immunotherapeutic agents in clinical development.
References
Larkin, J. et al. N. Engl. J. Med. 373, 23–34 (2015).
Wolchok, J. D. et al. N. Engl. J. Med. 377, 1345–1356 (2017).
Zakharia, Y. et al. Proc. AACR Ann. Meet. 77 (Suppl.), CT117 (2017).
Robert, C. et al. N. Engl. J. Med. 372, 2521–2532 (2015).
Ott, P. A. et al. Nature 547, 217–221 (2017).
Long, G. V. et al. J. Clin. Oncol. 34 (Suppl.) 9568–9568 (2016).